Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 3
1948 1
1949 3
1950 1
1951 3
1952 4
1953 4
1954 3
1955 1
1957 3
1958 2
1959 2
1961 4
1962 3
1963 6
1964 7
1965 4
1966 9
1967 9
1968 9
1969 13
1970 7
1971 8
1972 13
1973 20
1974 17
1975 19
1976 26
1977 18
1978 15
1979 31
1980 21
1981 25
1982 15
1983 25
1984 46
1985 40
1986 29
1987 44
1988 46
1989 55
1990 44
1991 34
1992 54
1993 47
1994 32
1995 35
1996 54
1997 40
1998 40
1999 27
2000 63
2001 48
2002 55
2003 51
2004 65
2005 78
2006 70
2007 83
2008 78
2009 90
2010 105
2011 122
2012 117
2013 130
2014 121
2015 123
2016 128
2017 138
2018 163
2019 146
2020 194
2021 206
2022 214
2023 221
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

3,470 results

Results by year

Filters applied: . Clear all
Page 1
Current best practice for bladder cancer: a narrative review of diagnostics and treatments.
Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Stenzl A, Thoeny HC, Witjes JA. Compérat E, et al. Lancet. 2022 Nov 12;400(10364):1712-1721. doi: 10.1016/S0140-6736(22)01188-6. Epub 2022 Sep 26. Lancet. 2022. PMID: 36174585 Review.
We discuss the current role of radiotherapy, surgical management of non-muscle-invasive and muscle-invasive disease, highlight the challenges of treatment of metastatic bladder cancer, and discuss the latest developments in systemic therapy. This Seminar is intended …
We discuss the current role of radiotherapy, surgical management of non-muscle-invasive and muscle-invasive disease, highlight the challenge …
Bladder Cancer: Diagnosis and Treatment.
DeGeorge KC, Holt HR, Hodges SC. DeGeorge KC, et al. Am Fam Physician. 2017 Oct 15;96(8):507-514. Am Fam Physician. 2017. PMID: 29094888 Free article. Review.
The most common clinical presentation is asymptomatic hematuria, which should prompt evaluation with cystoscopy, renal function testing, and upper urinary tract imaging in adults 35 years and older and in those with irritative voiding symptoms, risk factors for bladder …
The most common clinical presentation is asymptomatic hematuria, which should prompt evaluation with cystoscopy, renal function testing, and …
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Chang SS, et al. J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16. J Urol. 2016. PMID: 27317986 Review.
PURPOSE: Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and progression. ...Importantly, the evaluation and treatment algorithm takes into account tumor …
PURPOSE: Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) …
Application of nanotechnology in the diagnosis and treatment of bladder cancer.
Xu Y, Luo C, Wang J, Chen L, Chen J, Chen T, Zeng Q. Xu Y, et al. J Nanobiotechnology. 2021 Nov 27;19(1):393. doi: 10.1186/s12951-021-01104-y. J Nanobiotechnology. 2021. PMID: 34838048 Free PMC article. Review.
For example, gold nanoparticles (AuNPs) have been developed for simple, fast and sensitive urinary sample test for bladder cancer diagnosis. Nanoparticles targeting bladder cancers can facilitate to distinguish the normal and abnormal bladder tissues d …
For example, gold nanoparticles (AuNPs) have been developed for simple, fast and sensitive urinary sample test for bladder can …
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Powles T, et al. Ann Oncol. 2022 Mar;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012. Epub 2021 Nov 30. Ann Oncol. 2022. PMID: 34861372 Free article. No abstract available.
Advances in diagnosis and treatment of bladder cancer.
Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Lopez-Beltran A, et al. BMJ. 2024 Feb 12;384:e076743. doi: 10.1136/bmj-2023-076743. BMJ. 2024. PMID: 38346808 Review.
Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesica …
Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed ini …
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Tan WS, et al. Eur Urol Oncol. 2022 Oct;5(5):505-516. doi: 10.1016/j.euo.2022.05.005. Epub 2022 Jun 17. Eur Urol Oncol. 2022. PMID: 35718695 Review.
EVIDENCE SYNTHESIS: Variation exists between guidelines in defining IR NMIBC. The IBCG recommends defining IR NMIBC as any TaLG tumor that is either recurrent or multifocal or has size 3 cm, OR any T1LG tumor. ...The International Bladder Cancer Group recomme …
EVIDENCE SYNTHESIS: Variation exists between guidelines in defining IR NMIBC. The IBCG recommends defining IR NMIBC as any TaLG tumor …
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(): Under the Auspices of the EAU-ESMO Guidelines Committees.
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenz… See abstract for full author list ➔ Witjes JA, et al. Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19. Eur Urol. 2020. PMID: 31753752 Free article.
These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, …
These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the rol …
Management of metastatic bladder cancer.
Nadal R, Bellmunt J. Nadal R, et al. Cancer Treat Rev. 2019 Jun;76:10-21. doi: 10.1016/j.ctrv.2019.04.002. Epub 2019 Apr 15. Cancer Treat Rev. 2019. PMID: 31030123 Review.
Important advances in the understanding of the biology and mechanisms of tumor progression of urothelial carcinoma (UC) have been achieved over the past decade. ...Here we review the clinical trial data that have established standard-of-care treatment for advanced-s …
Important advances in the understanding of the biology and mechanisms of tumor progression of urothelial carcinoma (UC) have been ach …
3,470 results